Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation
© Albano et al.; licensee BioMed Central Ltd. 2013
Received: 13 February 2013
Accepted: 29 April 2013
Published: 4 May 2013
The t(9;22)(q34;q11) generating the BCR/ABL1 fusion gene represents the cytogenetic hallmark of chronic myeloid leukemia (CML). About 5–10% of CML cases show variant translocations with the involvement of other chromosomes in addition to chromosomes 9 and 22. The molecular bases of biological differences between CML patients with classic and variant t(9;22) have never been clarified.
In this study, we performed gene expression microarray analysis to compare CML patients bearing variant rearrangements and those with classic t(9;22)(q34;q11). We identified 59 differentially expressed genes significantly associated with the two analyzed groups. The role of specific candidate genes such as TRIB1 (tribbles homolog 1), PTK2B (protein tyrosine kinase 2 beta), and C5AR1 (complement component 5a receptor 1) is discussed.
Our results reveal that in CML cases with variant t(9;22) there is an enhancement of the MAPK pathway deregulation and show that kinases are a common target of molecular alterations in hematological disorders.
KeywordsChronic myeloid leukemia Variant t(9;22) rearrangements Gene expression profiling Protein kinases Cellular pathways
Chronic myeloid leukemia (CML) is a myeloproliferative disorder derived from hematopoietic stem cell transformation and characterized by heterogeneous biological and clinical features. The CML molecular marker is BCR/ABL1 fusion gene generation as a consequence of a reciprocal t(9;22)(q34;q11)[1, 2]. In most cases, the Philadelphia (Ph) chromosome is cytogenetically detectable but about 5–10% of CML patients show variant t(9;22)(q34;q11) rearrangements with the involvement of additional chromosomes[3, 4]. In these cases the BCR/ABL1 fusion gene can be revealed by Fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction. The occurrence of genomic microdeletions proximally to ABL1 or distally to BCR has been reported in CML cases with variant translocations with a greater frequency (30-40%) than in cases with classic t(9;22) (10-18%)[6, 7]. The prognostic significance of variant t(9;22) was unclear and debated in the pre-imatinib era, whereas recent studies of large CML series have reported that the presence of variant translocations has no impact on the cytogenetic and molecular response or on prognosis[6, 8]. However, the molecular bases of biological differences between CML patients with classic and variant t(9;22) have never been elucidated.
In this study, we performed gene expression profiling (GEP) by microarrays to identify a signature discriminating CML patients bearing variant rearrangements from those with classic t(9;22)(q34;q11). A list of 59 genes was found to be significantly associated with the two analyzed groups showing a differential expression. We applied network analysis to evaluate potential pathways involved in CML heterogeneity. An overall deregulation of genes encoding for protein kinases and involved in crucial cellular pathways such as MAPK (mitogen-activated protein kinase) signaling was found, unveiling the biological basis of differences in the CML patients subgroup with variant rearrangements.
Upregulation of kinases genes
Querying the Database for Annotation, Visualization and Integrated Discovery (DAVID) showed that the enhanced biological process in our gene set involved the intracellular protein kinases cascade, a series of reactions in which a signal is passed within the cell by sequential protein phosphorylation. This enhancement was significant (p = 0.003) and associated to a value of 7.6. In detail, the kinases list included 5 genes: TRIB1 (tribbles homolog 1), STK17B (serine/threonine kinase 17b), PTK2B (PTK2B protein tyrosine kinase 2 beta), C5AR1 (complement component 5a receptor 1) and ZFP36 (zinc finger protein 36, C3H type, homolog). Interestingly, TRIB1 resulted one of the highest expressed genes showing a 2.9-fold change in GEP experiments. The upregulation of all 5 kinases was confirmed by quantitative real-time polymerase chain reaction experiments (qRT-PCR) analysis, with statistically significant expression levels ranging from 2.20 to 8.02.
Involvement of kinases in the RAS/MAPK pathway
To date several profiling studies in CML have been reported focusing mainly on predicting response to imatinib therapy and identifying a gene-specific signature for different stages of the disease[13, 14]. Our GEP analysis performed on CML cases with variant t(9;22) may improve the understanding of the biological mechanisms at the basis of the CML heterogeneity. Overall, our results reveal that in CML cases with variant t(9;22) there is an enhancement of the MAPK pathway deregulation already known to underlie the CML pathogenesis and point out the role of interesting candidate genes, such as TRIB1, PTK2B, and C5AR1. These findings show that kinases are a common target of molecular alterations in hematological disorders and reinforce the idea that a perturbed action of signal transduction pathways is one of the hallmarks of cancer.
Chronic myeloid leukemia
Fluorescence In Situ Hybridization
Gene expression profiling
Mitogen-activated protein kinase
Database for Annotation, Visualization and Integrated Discovery
Tribbles homolog 1
B serine/threonine kinase 17b
PTK2B protein tyrosine kinase 2 beta
Complement component 5a receptor 1
Zinc finger protein 36, C3H type, homolog
Quantitative real-time polymerase chain reaction experiments
Ingenuity Pathways Analysis
Extracellular signal-regulated kinases
p38 mitogen-activated protein kinase
c-Jun N-terminal kinase
RAC-alpha serine/threonine-protein kinase
Mitogen activated protein kinase kinase
CCAAT⁄enhancer binding protein alpha
Mitogen-activated ERK kinase 1
MAP kinase kinase 4
Poly(rC) binding protein 2.
The authors would like to thank Ms. MVC Pragnell, B.A. for language revision of the manuscript.
This work was supported by “Fondazione Cassa di Risparmio di Puglia” and “Associazione Italiana contro le Leucemie (AIL)-BARI”.
- Goldman JM, Melo JV: Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med. 2003, 349: 1451-1464. 10.1056/NEJMra020777.View ArticlePubMedGoogle Scholar
- Melo JV, Barnes DJ: Chronic myeloid leukemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007, 7: 441-453. 10.1038/nrc2147.View ArticlePubMedGoogle Scholar
- Mitelman F, Johansson B, Mertens F: Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. 2012,http://www.cgap.nci.nih.gov/Chromosomes/Mitelman,Google Scholar
- Zagaria A, Anelli L, Albano F, Storlazzi CT, Liso A, Roberti MG, Buquicchio C, Liso V, Rocchi M, Specchia G: A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. Cancer Genet Cytogenet. 2004, 150: 81-85. 10.1016/j.cancergencyto.2003.08.018.View ArticlePubMedGoogle Scholar
- Landstrom AP, Tefferi A: Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma. 2006, 47: 397-402. 10.1080/10428190500353133.View ArticlePubMedGoogle Scholar
- Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood. 2001, 98: 1732-1738. 10.1182/blood.V98.6.1732.View ArticlePubMedGoogle Scholar
- Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Rossi AR, Vicari L, Liso V, Rocchi M, Specchia G: Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol Cancer. 2010, 9: 120-10.1186/1476-4598-9-120.PubMed CentralView ArticlePubMedGoogle Scholar
- Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G, Testoni N: Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011, 117: 6793-6800. 10.1182/blood-2011-01-328294.View ArticlePubMedGoogle Scholar
- Cilloni D, Saglio G: Molecular pathways: BCR-ABL. Clin Cancer Res. 2012, 18 (4): 930-937. 10.1158/1078-0432.CCR-10-1613.View ArticlePubMedGoogle Scholar
- Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T: Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood. 2010, 116: 2768-2775. 10.1182/blood-2009-10-246264.View ArticlePubMedGoogle Scholar
- Dougherty CJ, Kubasiak LA, Frazier DP, Li H, Xiong WC, Bishopric NH, Webster KA: Mitochondrial signals initiate the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation. FASEB J. 2004, 18: 1060-1070. 10.1096/fj.04-1505com.View ArticlePubMedGoogle Scholar
- Cao Q, McIsaac SM, Stadnyk AW: Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway. Am J Physiol Cell Physiol. 2012, 302: C1731-C1740. 10.1152/ajpcell.00213.2011.View ArticlePubMedGoogle Scholar
- Villuendas R, Steegmann JL, Pollán M, Tracey L, Granda A, Fernández-Ruiz E, Casado LF, Martínez J, Martínez P, Lombardía L, Villalón L, Odriozola J, Piris MA: Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 2006, 20: 1047-1054. 10.1038/sj.leu.2404197.View ArticlePubMedGoogle Scholar
- Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006, 103: 2794-2799. 10.1073/pnas.0510423103.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.